Supplementary Material

Supplementary Table S1. Multivariate analysis of radiographic progression-free survival

by blinded independent central review in the BRCA1/2 subgroup

	Model fit		HR	
Model parameter	Coeff (SE)	<i>P</i> value	Estimate (95% CI)	
Treatment (niraparib vs placebo)	-0.69 (0.18)	<0.0001	0.50 (0.35-0.71)	
Presence of visceral disease (no vs yes)	-0.75 (0.20)	0.0001	0.47 (0.32-0.69)	
Baseline PSA ^a	0.15 (0.04)	0.0001	1.16 (1.08-1.26)	

CI, confidence interval; HR, hazard ratio; PSA, prostate-specific antigen; SE, standard error.

^aThe logarithmic value of PSA was used.

Supplementary Table S2. Subsequent therapy for prostate cancer in the *BRCA1/2*

subgroup ^a

Therefore, $r(0/)$	NIRA + AAP	PBO + AAP	
Therapy, <i>n</i> (%)	(<i>n</i> = 113)	(n = 112)	
Total	35 (31.0)	66 (58.9)	
Chemotherapy	28 (24.8)	44 (39.3)	
Docetaxel	18 (15.9)	36 (32.1)	
Cabazitaxel	8 (7.1)	13 (11.6)	
Carboplatin	6 (5.3)	4 (3.6)	
Carboplatin/docetaxel	1 (0.9)	1 (0.9)	
Carboplatin:etoposide	1 (0.9)	0	
Cisplatin	1 (0.9)	2 (1.8)	
Etoposide	1 (0.9)	1 (0.9)	
Docetaxel/prednisone	0	1 (0.9)	
Estramustine	0	1 (0.9)	
Mitoxantrone	0	1 (0.9)	
Vinorelbine	0	1 (0.9)	
Other	11 (9.7)	18 (16.1)	
Prednisone	4 (3.5)	9 (8.0)	
Investigational drug	3 (2.7)	3 (2.7)	
Lutetium (Lu 177)	2 (1.8)	2 (1.8)	
Investigational antineoplastic drugs	1 (0.9)	2 (1.8)	
Prednisolone	1 (0.9)	0	
Radium Ra 223	1 (0.9)	1 (0.9)	
Dexamethasone	0	4 (3.6)	
Nivolumab	0	1 (0.9)	
Novel AR-targeted therapy	7 (6.2)	11 (9.8)	
Enzalutamide	7 (6.2)	10 (8.9)	
Apalutamide	0	1 (0.9)	
Hormonal	2 (1.8)	9 (8.0)	
Abiraterone	2 (1.8)	6 (5.4)	
Bicalutamide	0	2 (1.8)	
Flutamide	0	1 (0.9)	
PARPi	1 (0.9)	22 (19.6)	
Olaparib	1 (0.9)	18 (16.1)	
Fluzoparib	0	1 (0.9)	
Niraparib	0	2 (1.8)	
Rucaparib	0	1 (0.9)	
Talazoparib	0	1 (0.9)	

AAP, abiraterone acetate plus prednisone; AR, androgen receptor; NIRA, niraparib; /, poly

adenosine diphosphate-ribose polymerase inhibitor; PBO, placebo.

^aRecurrent medications were counted only once per patient.

	Median		Nominal	
	NIRA + AAP	PBO + AAP	HR (95% CI)	P value
	(<i>n</i> = 113)	(<i>n</i> = 112)		
Time to PSA progression	18.4	9.2	0.48 (0.33-0.70)	< 0.0001
Objective response rates	$28(50.0)^{a}$	$15(31.3)^{a}$	$1.60(0.98-2.62)^{b}$	0.053
OS multivariate analysis	NA	NA	0.68 (0.45-1.05)	0.0793
PSA response, $^{c} n (\%)$	93 (82.3)	77 (68.8)	1.21 (1.02-1.43) ^b	0.023
Confirmed	89 (78.8)	73 (65.2)		
Unconfirmed	4 (3.5)	4 (3.6)		

Supplementary Table S3. Other endpoints in the BRCA1/2 subgroup

AAP, abiraterone acetate with prednisone; AR, androgen receptor; CI, confidence interval; HR,

hazard ratio; NA, not available; NIRA, niraparib; OS, overall survival; PBO, placebo; PSA,

prostate-specific antigen.

^aResponder is presented as n (%) and represents a complete or partial response, neither of which

had to be confirmed.

^bRelative risk (95% CI); relative risk >1 favors active treatment.

^cPSA response rate was defined as the proportion of patients achieving a PSA decline of \geq 50%

and confirmed at 3-4 weeks later according to Prostate Cancer Working Group 3 criteria by week

12 and during the treatment period.

Supplementary Table S4. Multivariate analysis of OS by blinded independent central

review in the HRR+ population

	Model	HR	
Model parameter	Coeff (SE)	<i>P</i> value	Estimate (95% CI)
Treatment (niraparib vs placebo)	-0.21 (0.15)	0.1821	0.82 (0.60-1.10)
PSA ^a	0.09 (0.04)	0.0287	1.09 (1.01-1.18)
Lactate dehydrogenase ^a	0.52 (0.15)	0.0003	1.69 (1.27-2.25)
Alkaline phosphatase	0.28 (0.10)	0.0054	1.32 (1.09-1.61)
Age	0.03 (0.01)	0.0017	1.03 (1.01-1.05)
ECOG PS (0 vs 1)	-0.34 (0.16)	0.0339	0.71 (0.52-0.97)
Number of bone lesions at baseline $(\leq 10 \text{ vs} > 10)$	-0.60 (0.19)	0.0015	0.55 (0.38-0.80)
Presence of visceral disease (yes vs no)	0.43 (0.18)	0.0161	1.54 (1.08-2.18)

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status;

HR, hazard ratio; HRR, homologous recombination repair; OS, overall survival; PSA, prostate-

specific antigen; SE, standard error.

^aThe logarithmic value of PSA and lactate dehydrogenase was used.

			rPFS		TSP		TCC		OS
Gene	Treatment group	N (events)	HR (95% CI)	N (events)	HR (95% CI)	N (events)	HR (95% CI)	N (events)	HR (95% CI)
HRR-Fanconi Anemia (PALB2, BRIP1, FANCA)	NIRA + AAP PBO + AAP	17 (10) 14 (11)	0.68 (0.29-1.61)	17 (5) 14 (6)	0.61 (0.19-2.02)	17 (6) 14 (5)	0.73 (0.22-2.39)	17 (8) 14 (8)	0.71 (0.26-1.89)
PALB2	NIRA + AAP PBO + AAP	8 (6) 4 (4)	0.54 (0.14-2.03)	8 (1) 4 (2)	0.22 (0.02-2.42)	8 (3) 4 (1)	0.56 (0.05-6.41)	8 (4) 4 (3)	0.46 (0.10-2.08)
BRIP1	NIRA + AAP PBO + AAP	4 (2) 4 (3)	0.44 (0.07-2.65)	4 (2) 4 (1)	1.14 (0.10-13.27)	4 (2) 4 (0)	NE (NE)	4 (3) 4 (3)	0.40 (0.07-2.47)
FANCA	NIRA + AAP PBO + AAP	5 (2) 6 (4)	0.73 (0.13-4.06)	5 (2) 6 (3)	1.23 (0.17-8.74)	5 (1) 6 (4)	0.42 (0.04-4.03)	5 (1) 6 (2)	1.41 (0.09- 22.82)
HRR associated (<i>CHEK2</i> + <i>HDAC2</i>)	NIRA + AAP PBO + AAP	20 (12) 23 (14)	0.77 (0.36-1.68)	20 (4) 23 (7)	0.55 (0.16-1.88)	20 (6) 23 (7)	0.76 (0.26-2.27)	20 (8) 23 (12)	0.63 (0.26-1.55)
CHEK2	NIRA + AAP PBO + AAP	18 (11) 20 (11)	0.87 (0.37-2.01)	18 (3) 20 (6)	0.48 (0.12-1.94)	18 (4) 20 (7)	0.49 (0.14-1.69)	18 (7) 20 (10)	0.66 (0.25-1.75)
HDAC2	NIRA + AAP PBO + AAP	2 (1) 3 (3)	0.71 (0.06-8.02)	2 (1) 3 (1)	0.71 (0.04-11.79)	2 (2) 3 (0)	NE (NE)	2 (1) 3 (2)	0.44 (0.04-5.13)
ATM	NIRA + AAP PBO + AAP	43 (32) 42 (25)	1.26 (0.74-2.13)	43 (9) 42 (11)	0.79 (0.33-1.90)	43 (9) 42 (16)	0.47 (0.21-1.06)	43 (17) 42 (14)	1.13 (0.56-2.30)
CDK12	NIRA + AAP PBO + AAP	11 (7) 16 (10)	0.89 (0.34-2.36)	11 (4) 16 (5)	1.05 (0.28-3.94)	11 (5) 16 (6)	1.32 (0.38-4.56)	11 (6) 16 (9)	1.30 (0.45-3.81

Supplementary Table S5. Key efficacy endpoints by gene alteration in the HRR+ population

AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; HRR, homologous recombination repair; NE, not


estimable; NIRA, niraparib; OS, overall survival; PBO, placebo; PSA, prostate-specific antigen; rPFS, radiographic progression-free

survival; TCC, time to initiation of cytotoxic chemotherapy; TSP, time to symptomatic progression.

Note: Nonestimable HRs are due to few or no events.


Supplementary Figure S1. CONSORT diagram.


AAP, abiraterone acetate with prednisone; HRR, homologous recombination repair; NIRA, niraparib; PBO, placebo. ^aIncluded 3166 patients who entered prescreening *de novo* (did not have known HRR status).




Supplementary Figure S2. Radiographic progression-free survival at IA2 assessed (A) in the *BRCA1/2* subgroup as analyzed by investigator review, (B) in the HRR+ population as analyzed by blinded independent central review, and (C) in the HRR+ population as analyzed by investigator review.

AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; HRR, homologous recombination repair; IA2, second interim analysis; NIRA, niraparib; PBO, placebo. ^aNominal *P* value.







Supplementary Figure S3. Radiographic progression-free survival by baseline patient and disease characteristics for the *BRCA1/2* subgroup.


AAP, abiraterone acetate with prednisone; AR, androgen receptor; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NE, not evaluable; PAC, Pacific; PSA, prostate-specific antigen.

		Median	(months)		
Variable	Subgroup	PBO + AAP	NIRA + AAP		HR (95% CI)
All patients	All	10.9	19.5	⊢●⊣	0.55 (0.39-0.78)
	< 65	13.6	13.9	⊢_● I	0.82 (0.45-1.47)
Age group, y	≥ 65-74	9.7	29.3	⊢_●	0.34 (0.19-0.60)
	≥ 75	9.0	16.5	⊢ ● <u></u>	0.71 (0.36-1.40)
	Asian	8.3	NE	⊢	0.27 (0.10-0.70)
Race group	White	11.0	16.5	⊢● (0.65 (0.44-0.97)
	Other	10.9	19.5	⊢	0.42 (0.14-1.28)
Baseline ECOG PS	0	11.2	22.5	⊢●-1	0.41 (0.26-0.65)
saseline ECOG PS	1	8.3	13.9	⊢ ● <u></u> +	0.78 (0.44-1.38)
	0	11.0	22.2	⊢●	0.47 (0.29-0.77)
Baseline BPI-SF#3 score	1 to 3	8.4	16.6	⊢● →	0.63 (0.37-1.06)
	> 3	13.7	NE	⊢	0.61 (0.13-2.87)
	Asia-PAC	10.9	NE	⊢	0.33 (0.14-0.73)
Region	Europe	8.7	16.7	⊢ ●−1	0.59 (0.38-0.92)
	North/South America	12.4	19.6	⊢ ● <u></u>	0.75 (0.35-1.61)
^o ast taxane-based	Yes	13.7	13.4		0.98 (0.48-2.02)
chemotherapy	No	10.9	22.2	⊢ ●–1	0.47 (0.31-0.69)
Past AR-targeted	Yes	4.3	NE	• •	0.11 (0.01-1.12)
herapy	No	11.0	19.5	⊢● -1	0.57 (0.40-0.81)
Prior AAP use	Yes	13.7	16.1	⊢ ● − −1	0.82 (0.41-1.67)
Phor AAP use	No	8.4	19.6	⊢●	0.49 (0.33-0.73)
Presence of visceral	Yes	7.2	8.2	⊢	0.97 (0.51-1.86)
metastases	No	11.1	25.1	⊢●	0.41 (0.27-0.62)
Bone-only	Yes	16.4	25.1	⊢ ●j	0.56 (0.30-1.04)
metastasis at entry	No	8.3	16.5	⊢● -1	0.50 (0.33-0.75)
Number of bone	≤ 10	13.6	22.2	⊢● -	0.53 (0.34-0.84)
esions at baseline	> 10	8.1	16.1	⊢ ●	0.54 (0.32-0.93)
Baseline PSA above	Yes	8.2	16.7	⊢● –1	0.39 (0.23-0.64)
median	No	13.8	22.0	⊢●	0.65 (0.40-1.06)
				0.1 1	
				Favoring niraparib Favoring p	lacebo
			<		>

Supplementary Figure S4. Time to symptomatic progression at IA2 in the HRR+

population.


AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; HRR, homologous recombination repair; IA2, second interim analysis; NE, not evaluable; NIRA, niraparib; PBO, placebo.



Supplementary Figure S5. Time to initiation of cytotoxic chemotherapy at IA2 in the


HRR+ population.


AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; HRR, homologous recombination repair; IA2, second interim analysis; NE, not evaluable; NIRA, niraparib; PBO, placebo.



Supplementary Figure S6. Overall survival at IA2 in the HRR+ population by (A) stratified analysis and (B) IPCW analysis.

AAP, abiraterone acetate with prednisone; CI, confidence interval; HR, hazard ratio; HRR, homologous recombination repair; IA2, second interim analysis; IPCW, inverse probability censoring weighting; NIRA, niraparib; PBO, placebo. ^aNominal *P* value.





Supplementary Figure S7. Additional endpoints at IA2 in the BRCA1/2 subgroup,

including (A) time to pain progression and (B) time to BPI-SF pain interference.

AAP, abiraterone acetate with prednisone; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; HR, hazard ratio; IA2, second interim analysis; NE, not evaluable; NIRA, niraparib; PBO, placebo. ^aNominal *P* value.

